El Salvador's Ambassador to the United States to Represent the El Salvador People at GBA's Blockchain & Sustainable Economic Growth Conference

Washington, D.C., May 16, 2022 - (JCN Newswire) - Milena Mayorga, El Salvador's ambassador to the United States, will represent her nation and government at this year's Blockchain & Sustainable Economic Growth Conference organized by the Government Blockchain Association.

The conference will focus on blockchain technology in business and government. It will include presentations from experts in the field and a Pitch Competition, Job Fair, and Art Show.

H.E. Ambassador Mayorga is a former deputy to the Legislative Assembly of El Salvador and a former model who represented El Salvador in the Miss Universe 1996 pageant. On September 24, 2020, President Nayib Bukele appointed her as Ambassador to the United States.

On May 25-27, the GBA will host the Blockchain & Sustainable Economic Growth Conference at the historic Mayflower Hotel in Washington, DC. For more information, please click here: https://gbaglobal.org/blockchain-sustainable-economic-growth/.

The Government Blockchain Association is an industry group devoted to educating and encouraging the usage of blockchain technology across the world.

Despite international criticism, President Nayib Bukele's forward-thinking government legalized bitcoin in late 2021, making it the first nation to do so.

Source: Platoblockchain.com (https://platoblockchain.com)


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/yp3etlG

TJI Achieves a Successful Leap to International Market

HONG KONG, May 16, 2022 - (ACN Newswire) - Tam Jai International Co. Limited ("TJI" or the "Company", and together with its subsidiaries, the "Group"; HKEX stock code: 2217), a leading and renowned mixian-specialised fast casual restaurant chain, announced its first annual results after its listing in Hong Kong. Revenue of the Group saw a notable year-on-year increase of 26.8% to HK$2,275.3 million for the year ended 31 March 2022 ("FY2022"), despite the 5th wave of COVID-19 outbreak in Hong Kong in the last quarter of FY2022. Excluding one-off listing expenses and government subsidies in relation to COVID-19, its adjusted profit for the year rose by 17.8% to HK$165.5 million in FY2022.

Highlights
Prominent Performance in FY2022
-- Revenue increased by 26.8% to HK$2,275.3 million year-on-year, mainly attributable to the increased number of restaurants in operation and growth in comparable restaurants revenue
-- Operating profit of restaurant operations increased by 38.2% to HK$476.7 million
-- Operating profit margin up by 1.7 percentage points to 20.9%
-- Excluding the one-off listing expenses and government subsidies in relation to COVID-19, adjusted profit for the year increased by 17.8% to HK$165.5 million

Expanding Restaurant Network
-- The unique and authentic TamJai tastes were successfully brought to different regions. The responses the Group has received from Shenzhen, Guangzhou and Tokyo were instantaneous and overwhelming
-- As at 31 March 2022, there were 175 restaurants in operation across Hong Kong, Mainland China, Singapore and Japan, a net increase of 28 restaurants as compared to 31 March 2021
-- Eight restaurants were opened in the Mainland China and the first restaurant in Japan was met with a rapturous reception
-- TJI aims to further expand its restaurant network in Hong Kong, the Greater Bay Area, Singapore and Japan, with two more restaurants planned to open in Kichijoji and Ebisu in Tokyo, Japan in the first quarter of FY2023

Revenue of TJI's Hong Kong restaurants saw a speedy and strong recovery to the pre-COVID-19 level during the first three quarters of FY2022 as the pandemic eased. This was due to the support of a community of loyal customers as it consistently delivers quality food with a variety of options and exceptional service. While the entire catering industry in Hong Kong was reeling from the impact of COVID-19 outbreak in the fourth quarter of FY2022, the Group managed to stay afloat thanks to its wide brand recognition, great success of the introduction of premium toppings, snacks and new products, and the continued support from its loyal customers.

The rise in revenue in FY2022 was mainly attributable to the increase in the number of restaurants in operation, and the steady growth in comparable restaurants revenue in Hong Kong. Meanwhile, operating profit increased by 38.2% to HK$476.7 million, with operating profit margin improving by 1.7 percentage points to 20.9%. This was due to the decrease in staff costs as a percentage of revenue attributable to the improvement of manpower efficiency, and the decrease in depreciation of right-of-use assets, rental and related expenses as a percentage of revenue, attributable to the improvement in its restaurant performance. The Group also continued to achieve a healthy financial position and had cash and cash equivalents of HK$1,365.2 million as at 31 March 2022.

The Board recommends paying a final dividend of HK11.4 cents per share for FY2022, or approximately HK$152.4 million in total.

Business Review
Steady comparable restaurants revenue growth despite 5th wave of COVID-19 outbreak
As part of its strategies in menu design, TJI has launched more than two dozen new products in FY2022 including toppings, soup base, snacks and beverages. The introduction of premium toppings and snacks, combined with successful marketing campaigns as well as a menu price adjustment in February 2022, resulted in an across-the-board increase in the average spending per customer, and the average daily number of bowls served per seat.

During the first three quarters of FY2022, the comparable revenue of TJI's Hong Kong restaurants had recovered to the pre-COVID-19 level. To mitigate the impact of the 5th wave of COVID-19 outbreak in the last quarter of FY2022, the Group had quickly boosted its takeaway/food delivery capacity, by offering takeaway promotions and maintaining a strong partnership with third-party delivery platforms. It has also carefully managed its supply chain and workforce to minimise service interruptions amid the pandemic. The decrease in dine-in revenue in the last quarter of FY2022 was partially offset by the increase in proportion of takeaway/food delivery revenue.

Striving for improvements
Despite global logistics interruptions, and the upward pressure on the cost of food and beverages consumed in face of the ongoing pandemic, the Group managed to mitigate general cost inflation through supply chain management, and product substitution or upgrade. The integration of the central kitchens of TamJai Yunnan Mixian ("TamJai") and TamJai SamGor Mixian ("SamGor") brands also contributed to the reduction in the costs in facilities, enhancement in efficiency, and optimisation of food production. New supply chain management systems were also set up to optimise cost control and to enhance production planning process.

In addition, a Smart Rostering was implemented to help maintain the right level of frontline staff and productivity, and thereby optimise labour costs, as business volume fluctuates in tandem with the pandemic situation. It also made swift decisions regarding restaurant operating hours, renovation projects and restaurant opening schedule by re-assessing the market needs.

Expansion of restaurant network
As of 31 March 2022, TJI operates a total of 175 restaurants, with geographical presence expanding to Japan on 31 March 2022, in addition to the existing markets of Hong Kong, Mainland China and Singapore. The responses it has received from its first restaurant in Japan were overwhelming: hundreds of customers queued for hours outside its Shinjuku restaurant in Tokyo, eager to be among the first to enjoy a steaming noodle bowl packed with Hong Kong flavours and culture. There is clearly an international appetite for authentic Hong Kong food experience. And this has encouraged TJI to continue looking for new global avenues to bring the perfect taste abroad.

In Hong Kong, the Group operates 81 TamJai restaurants, and 81 SamGor restaurants. Its expanding restaurant network is complementary to the delivery service coverage throughout the city, as it is aware of the importance of takeaway and delivery in the industry amid the ongoing pandemic.

In Mainland China, the Group has opened eight restaurants in total under TamJai brand for FY2022, including six in Shenzhen, and two in Guangzhou. In the financial year ending 31 March 2023 ("FY2023"), it plans to open more restaurants in the Greater Bay Area as strategies are being put in place to drive both dine-in and takeaway turnovers.

In Singapore, one new restaurant was opened in March 2022, and some locations of new restaurants have been confirmed in the pipeline for FY2023.

TJI also opened its first restaurant in Shinjuku, Japan on 31 March 2022, and plans to open two more restaurants located in Kichijoji and Ebisu in Tokyo in the first quarter of FY2023.

Prospects
While the past year has been a bumpy ride, TJI has demonstrated resilience and agility in face of unanticipated situations. As the pandemic enters its third year, the Group is optimistic that social restrictions will be lifted gradually, and its growth momentum should resume in Hong Kong, Mainland China, and the overseas markets.

In tune with the fast-changing customer behaviour in tandem with the pandemic's development, the Group is investing in further enhancing its restaurant-level efficiency in serving dine-in, takeaway and delivery orders. It is also implementing new supply chain management systems in Hong Kong and other markets to optimise cost control and enhance production planning process, which would help cushion itself against logistics hiccoughs and changes in COVID-related policies on movements and mobility.

For the Mainland China market, the initial revenue and customers responses of the new restaurants in Shenzhen and Guangzhou had been favourable, and the business is expected to pick up as soon as the social activities resume.

Riding on the strong rebound in the Singapore market since November 2021, the Group will resume new restaurant opening activities, and adapt its business model to capitalise on the revived consumer sentiment and increase profitability. Besides, it has been encouraged by the rapturous reception of its first restaurant in Tokyo. As market activities have started picking up again in Japan, TJI will keep expanding its network healthily to capture the market momentum with the robust support of its controlling shareholder, Toridoll Holdings Corporation.

Mr. Daren Lau, Chairman, Executive Director and Chief Executive Officer of TJI, said, "We are very pleased to have navigated through the challenges posed by the pandemic in FY2022 with great agility and resilience as we continued to grow our revenue and operating profit margin. The encouraging results have proved our competitive advantages in food and service quality, restaurant operations and supply chain management. On the back of our successful listing in Hong Kong in October 2021, we will further expand our market presence, and bring our one-of-a-kind chain restaurant dining experience and distinctive 'TamJai Tastes' all over the world."

About Tam Jai International Co. Limited (HKEX: 2217)
TJI has been listed on The Stock Exchange of Hong Kong Limited (stock code: 02217.HK) since October 2021. It is one of the largest and most popular fast casual resturant chains and the No.1 Asian noodle specialty restaurant operator in Hong Kong.* It primarily operates the TamJai Yunnan Mixian and TamJai SamGor Mixian brands, with operations in Hong Kong, Mainland China, Singapore and Japan. As at 31 March 2022, the Group operated a total of 175 restaurants. With the first TamJai Yunnan Mixian restaurant and the first TamJai SamGor Mixian restaurant opened in 1996 and 2008 in Hong Kong respectively, it has pioneered and popularised the new mixian trend in Hong Kong.

*In terms of both revenue and number of restaurants in 2020, according to Euromonitor


Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.com

source https://www.acnnewswire.com/press-release/english/75202/

The Executive Talk: Kerry Express (Thailand) PCL (SET: KEX)

BANGKOK, May 16, 2022 - (JCN Newswire) - Kerry Express (Thailand) PCL (SET: KEX) Chief Executive Officer, Mr. Alex Ng discusses the company's strategy behind its achievement as the leading express parcel delivery in the country in The Executive Talk (TET) by ShareInvestor.

1. Last year, the COVID-19 pandemic massively affected the economy. How has it challenged your business, and how did you cope with it?

Many people understand that Kerry must benefit from COVID-19 because more and more people shop online during the lockdown. Therefore, we have to deliver these parcels to their homes. So yes, in terms of business growth, we have experienced recorded high business growth in the past couple of years. But generally speaking, we do not like Covid-19. It disturbed our daily operations in a very big way. The supply of manpower, truck movement, and resource management planning got very difficult. Therefore, we all hope that the Covid-19 crisis will end soon.

However, I must admit that we managed the crisis very well while many transportation, logistics, and express companies did not effectively plan or overprepare for the situation. You may have read on the news that some companies got disrupted. Some had to suspend their sorting processes, while others even had to close their warehouses. But Kerry maintained very good continuity during COVID-19. It is payback for our dedication and well-plan. We now work 24-7, 365 days, and have no holidays.

2. What do you think has proved your market-leading position in Thailand?

First of all, we are the listed company with strong capital. As many logistics companies struggle with financial difficulties, Kerry Express focuses on improving our operations, such as business strategy and human development. So, we are more focused. At the same time, we are not very bureaucratic. While many listed companies or large corporations can be very bureaucratic, Kerry is an entrepreneurial organization with high mobility and flexibility, which is one of our strengths. However, the most important thing for me is that Kerry Express is very customer addicted. If you sit in any of our meetings, we always talk about how to make our customers happier and happier, how to make our great operations even better. We always want to be a better person, better company than yesterday.

3. What do you see as the major threats these days?

As you know, we are in wartime. Indeed, the oil price does not affect us very much. On the contrary, we spend less on fuel costs because of our reengineering, making our delivery and transportation more efficient. But if oil prices continue to increase, it will probably bring high pressure on our finances and operation sooner or later. Therefore, we are working very hard to be more efficient and rely less on fuel.

In addition, another issue for Thailand and this region is human capital. Today it is getting harder to find the right talent to work for a corporation. It's not because they're not smart or young people are not hard-working or progressive. But today, it's very dynamic, and the working culture is different from ten years or two decades ago. So, I think a corporation like Kerry needs to change to a new paradigm. It seems employees embrace much more individuality than they were twenty years ago. The relationship between employer and employee becomes more parallelly. Consequently, we have tried to adjust ourselves, such as a friendly workplace. We try to make our office and working environment much happier for the employees so that we get the best talents in the country and the region. People are our only asset, I would say.

4. How would you enlarge your business ecosystem? Will any new services be coming this year or in 2023?

We will never stop developing new products and services. Express and parcel delivery remains our core business. But the expansion of new services will bring more users and sticky users. You would have heard that we're launching a new service that delivers frozen and chilled products called "Kerry Cool." No one is doing it seriously in the country. And most recently, we have just announced a new service with Central Group, "Kerry XL." We are moving larger items like furniture and gym devices. So, we are creating a new delivery platform that does not overlap with our existing service.

Furthermore, we are also developing a non-delivery platform rapidly. We have built a new payment platform called "Kerry Wallet" that combines various payment methods, including credit cards, top-up wallets, and PromptPay's QR Code system. Because during the Covid-19, a number of users have turned to cashless payment. We are happy to contain these users within Kerry Wallet, so they enjoy better and more convenience.

5. How have you prepared to enter digital technology dynamics?

From my perspective, preparing for the digital economy is not one of the exercises. Indeed, Kerry has never stopped digitalizing since day one. Can you imagine we were the first to invent cash-on-delivery in Thailand? And it's us again who started the QR Code payment on delivery. We doubt many people know, but our frequent customers have gradually turned to this payment method. We are a very innovative company. We will not announce it as a showcase because this kind of thing is not a showcase but a real necessity for the company's development.

6. Can you tell us about "HI-STEP", Kerry Express's core value?

"HI-STEP" is our motto, not created by the management but by most employees about eight years ago in the workshop. H stands for honesty, I for innovation, S for service mind, T for teamwork, E for execution, and last but not least, P stands for positivity because we want our people to be positive-minded, not negative-minded. These are elements or core competence that we believe Kerry people shall possess. They even composed a song about it. You can listen on YouTube. ( https://youtu.be/pi32iVaCdvs )

About The Executive Q&A Series

The Executive Q&A Series is presented by ShareInvestor, Asia's leading financial internet media and technology company and the largest investor relations network in the region. For more information, email admin.th@shareinvestor.com. Website: www.ShareInvestorThailand.com


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/yp3etlG

The Executive Talk: Kerry Express (Thailand) PCL (SET: KEX)

BANGKOK, May 16, 2022 - (ACN Newswire) - Kerry Express (Thailand) PCL (SET: KEX) Chief Executive Officer, Mr. Alex Ng discusses the company's strategy behind its achievement as the leading express parcel delivery in the country in The Executive Talk (TET) by ShareInvestor.

1. Last year, the COVID-19 pandemic massively affected the economy. How has it challenged your business, and how did you cope with it?

Many people understand that Kerry must benefit from COVID-19 because more and more people shop online during the lockdown. Therefore, we have to deliver these parcels to their homes. So yes, in terms of business growth, we have experienced recorded high business growth in the past couple of years. But generally speaking, we do not like Covid-19. It disturbed our daily operations in a very big way. The supply of manpower, truck movement, and resource management planning got very difficult. Therefore, we all hope that the Covid-19 crisis will end soon.

However, I must admit that we managed the crisis very well while many transportation, logistics, and express companies did not effectively plan or overprepare for the situation. You may have read on the news that some companies got disrupted. Some had to suspend their sorting processes, while others even had to close their warehouses. But Kerry maintained very good continuity during COVID-19. It is payback for our dedication and well-plan. We now work 24-7, 365 days, and have no holidays.

2. What do you think has proved your market-leading position in Thailand?

First of all, we are the listed company with strong capital. As many logistics companies struggle with financial difficulties, Kerry Express focuses on improving our operations, such as business strategy and human development. So, we are more focused. At the same time, we are not very bureaucratic. While many listed companies or large corporations can be very bureaucratic, Kerry is an entrepreneurial organization with high mobility and flexibility, which is one of our strengths. However, the most important thing for me is that Kerry Express is very customer addicted. If you sit in any of our meetings, we always talk about how to make our customers happier and happier, how to make our great operations even better. We always want to be a better person, better company than yesterday.

3. What do you see as the major threats these days?

As you know, we are in wartime. Indeed, the oil price does not affect us very much. On the contrary, we spend less on fuel costs because of our reengineering, making our delivery and transportation more efficient. But if oil prices continue to increase, it will probably bring high pressure on our finances and operation sooner or later. Therefore, we are working very hard to be more efficient and rely less on fuel.

In addition, another issue for Thailand and this region is human capital. Today it is getting harder to find the right talent to work for a corporation. It's not because they're not smart or young people are not hard-working or progressive. But today, it's very dynamic, and the working culture is different from ten years or two decades ago. So, I think a corporation like Kerry needs to change to a new paradigm. It seems employees embrace much more individuality than they were twenty years ago. The relationship between employer and employee becomes more parallelly. Consequently, we have tried to adjust ourselves, such as a friendly workplace. We try to make our office and working environment much happier for the employees so that we get the best talents in the country and the region. People are our only asset, I would say.

4. How would you enlarge your business ecosystem? Will any new services be coming this year or in 2023?

We will never stop developing new products and services. Express and parcel delivery remains our core business. But the expansion of new services will bring more users and sticky users. You would have heard that we're launching a new service that delivers frozen and chilled products called "Kerry Cool." No one is doing it seriously in the country. And most recently, we have just announced a new service with Central Group, "Kerry XL." We are moving larger items like furniture and gym devices. So, we are creating a new delivery platform that does not overlap with our existing service.

Furthermore, we are also developing a non-delivery platform rapidly. We have built a new payment platform called "Kerry Wallet" that combines various payment methods, including credit cards, top-up wallets, and PromptPay's QR Code system. Because during the Covid-19, a number of users have turned to cashless payment. We are happy to contain these users within Kerry Wallet, so they enjoy better and more convenience.

5. How have you prepared to enter digital technology dynamics?

From my perspective, preparing for the digital economy is not one of the exercises. Indeed, Kerry has never stopped digitalizing since day one. Can you imagine we were the first to invent cash-on-delivery in Thailand? And it's us again who started the QR Code payment on delivery. We doubt many people know, but our frequent customers have gradually turned to this payment method. We are a very innovative company. We will not announce it as a showcase because this kind of thing is not a showcase but a real necessity for the company's development.

6. Can you tell us about "HI-STEP", Kerry Express's core value?

"HI-STEP" is our motto, not created by the management but by most employees about eight years ago in the workshop. H stands for honesty, I for innovation, S for service mind, T for teamwork, E for execution, and last but not least, P stands for positivity because we want our people to be positive-minded, not negative-minded. These are elements or core competence that we believe Kerry people shall possess. They even composed a song about it. You can listen on YouTube. ( https://youtu.be/pi32iVaCdvs )

About The Executive Q&A Series

The Executive Q&A Series is presented by ShareInvestor, Asia's leading financial internet media and technology company and the largest investor relations network in the region. For more information, email admin.th@shareinvestor.com. Website: www.ShareInvestorThailand.com

Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.com

source https://www.acnnewswire.com/press-release/english/75199/

Solve.Care Foundation CEO Pradeep Goel to Speak about Blockchain Technology in Healthcare at GBA's Blockchain & Sustainable Economic Growth Conference

Washington, D.C., May 16, 2022 - (JCN Newswire) - Government Blockchain Association is proud to announce that Pradeep Goel, CEO of Solve.Care Foundation, will speak about blockchain technology in healthcare at the upcoming GBA Blockchain & Sustainable Economic Growth Conference (https://gbaglobal.org/2022-bcseg-tickets/) on May 25-27, 2022 at Mayflower Hotel in Washington, DC.

Mr. Goel is a healthcare executive with a relentless focus on improving healthcare administration, coordination, quality, and efficiency by using blockchain in healthcare today.

With 25 years of expertise in the health sector as a CEO, COO, CIO, and CTO in insurance, benefits administration, and public programs, Mr. Goel is the ideal individual to discuss the implementation of blockchain in healthcare today

Furthermore, Mr. Goel will describe how he stayed in Ukraine after the country's illegal occupation by Russia began and how he and his Solve.Care team created nine refugee shelters for displaced Ukrainians who had lost their homes due to Russia's invasion of their homeland.

His talk will be immensely informative for all those attending the conference, so don't miss out and register today. Don't pass up the chance to hear from one of the world's foremost blockchain healthcare experts.

Please register today and join us at the GBA Blockchain & Sustainable Economic Growth Conference to learn more about how blockchain technology is implemented globally in healthcare systems. You won't regret it!

The Government Blockchain Association is an industry association dedicated to the education and ethical adoption of blockchain-based solutions globally.

Solve.Care Foundation is a blockchain-powered platform that allows for a more cost-effective, coordinated, and patient-centric healthcare delivery. Its mission is to make access to quality healthcare a fundamental human right by leveraging the power of blockchain technology.

Source: Platoblockchain.com (https://platoblockchain.com)


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/yp3etlG

Solve.Care Foundation CEO Pradeep Goel to Speak about Blockchain Technology in Healthcare at GBA's Blockchain & Sustainable Economic Growth Conference

Washington, D.C., May 16, 2022 - (ACN Newswire) - Government Blockchain Association is proud to announce that Pradeep Goel, CEO of Solve.Care Foundation, will speak about blockchain technology in healthcare at the upcoming GBA Blockchain & Sustainable Economic Growth Conference (https://gbaglobal.org/2022-bcseg-tickets/) on May 25-27, 2022 at Mayflower Hotel in Washington, DC.

Pradeep Goel, CEO of Solve.Care Foundation


Mr. Goel is a healthcare executive with a relentless focus on improving healthcare administration, coordination, quality, and efficiency by using blockchain in healthcare today.

With 25 years of expertise in the health sector as a CEO, COO, CIO, and CTO in insurance, benefits administration, and public programs, Mr. Goel is the ideal individual to discuss the implementation of blockchain in healthcare today

Furthermore, Mr. Goel will describe how he stayed in Ukraine after the country's illegal occupation by Russia began and how he and his Solve.Care team created nine refugee shelters for displaced Ukrainians who had lost their homes due to Russia's invasion of their homeland.

His talk will be immensely informative for all those attending the conference, so don't miss out and register today. Don't pass up the chance to hear from one of the world's foremost blockchain healthcare experts.

Please register today and join us at the GBA Blockchain & Sustainable Economic Growth Conference to learn more about how blockchain technology is implemented globally in healthcare systems. You won't regret it!

The Government Blockchain Association is an industry association dedicated to the education and ethical adoption of blockchain-based solutions globally.

Solve.Care Foundation is a blockchain-powered platform that allows for a more cost-effective, coordinated, and patient-centric healthcare delivery. Its mission is to make access to quality healthcare a fundamental human right by leveraging the power of blockchain technology.

Source: Platoblockchain.com (https://platoblockchain.com)

Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.com

source https://www.acnnewswire.com/press-release/english/75196/

Nissin Foods Achieves Steady 2022 Q1 Financial Results

HONG KONG, May 13, 2022 - (ACN Newswire) - Nissin Foods Company Limited ("Nissin Foods" or the "Company", and together with its subsidiaries, the "Group"; Stock code: 1475) today announced its unaudited first quarter financial information for the three months ended 31 March 2022 ("the Reporting Period").

The Group's revenue increased by 10.1% year-on-year ("YoY") from HK$964.5 million to HK$1,061.8 million. Gross profit grew 7.4% YoY to HK$332.8 million (2021: HK$309.9 million). Gross profit margin was 31.3% (2021: 32.1%), mainly a result of the increased prices of raw materials and other production costs. Profit attributable to owners of the Company was HK$90.3 million (2021: HK$93.2 million).

Revenue from Hong Kong operations increased by 6.6% YoY to HK$357.9 million due to a surge in demand of bag-type instant noodles. As for Mainland China operations, having taken steps to expand its geographical sales territories and strengthen its "Cup Noodles" brand in the Reporting Period, revenue increased by 11.9% (in local currency: 8.6%) to HK$703.9 million, mainly contributed by the growth in sales volume of cup-type instant noodles.

Mr Kiyotaka ANDO, Executive Director, Chairman and Chief Executive Officer of Nissin Foods, said, "With the COVID-19 epidemic prevailing, people's livelihood and economic recovery have been surrounded with uncertainties. Although the business environment has been challenging, we are committed to ensuring stable supply of quality and safe products to our customers and, to sustain profit growth. We will continue to enhance production efficiency by improving our capabilities and implementing cost-saving measures. In line with the Company's strategic direction, we will also continue to enhance our product portfolio so as to strengthen overall competitiveness and create sustainable value for all stakeholders."

For details, please refer to the announcement:
https://www1.hkexnews.hk/listedco/listconews/sehk/2022/0513/2022051300230.pdf

About Nissin Foods Company Limited
Nissin Foods Company Limited (The "Group"; Stock code: 1475) is a renowned food company in Hong Kong and Mainland China with a diversified portfolio of well-known and highly popular brands and the largest instant noodle company in Hong Kong. The Group officially established its presence in Hong Kong in 1984. The Group primarily manufactures and sells instant noodles, frozen foods and other food products under its two core corporate brands, namely "NISSIN" and "DOLL" together with a diversified portfolio of iconic household premium food brands. The Group's five flagship product brands, namely "Cup Noodles", "Demae Iccho", "Doll Instant Noodle", "Doll Dim Sum" and "Fuku" are also among the most popular choices in their respective food product categories in Hong Kong. In the Mainland China market, the Group has introduced technology innovation through the "ECO Cup" concept and primarily focuses its sales efforts in first-and second-tier cities.

Nissin Foods is a constituent of eight Hang Seng Indexes, namely: Hang Seng Composite Index, Hang Seng Consumer Goods & Services Index, Hang Seng Stock Connect Hong Kong Index, Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index, Hang Seng Stock Connect Hong Kong SmallCap Index, Hang Seng SCHK Mainland China Companies Index, Hang Seng SCHK ex-AH Companies Index, and Hang Seng Small Cap (Investable) Index. For more information, please visit www.nissingroup.com.hk.


Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.com

source https://www.acnnewswire.com/press-release/english/75179/

Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine

SHANGHAI, CHINA, May 13, 2022 - (ACN Newswire) - Hua Medicine (the "Company", stock code on the main board of the Hong Kong Stock Exchange: 2552.HK) today announces that, two peer-reviewed papers on the Phase III clinical trial results of dorzagliatin, a glucokinase activator (GKA) and first-in-class investigational drug of the Company for the treatment of diabetes, were published online simultaneously by Nature Medicine, an international top medical journal. These two papers described and analyzed the clinical efficacy and safety characteristics of dorzagliatin monotherapy (SEED) in drug-naive Type 2 diabetes (T2D) patients and the combination therapy of dorzagliatin and metformin (DAWN) in patients who failed in metformin adequacy therapy for the treatment of T2D respectively.



It was the first time for Nature Medicine to publish the results of Phase III trials of a GKA, representing the results of large registered clinical studies in China. Dorzagliatin is a new first-in-class GKA antidiabetic drug to successfully complete the Phase III registered clinical study in the world, which was led by Chinese researchers. The two papers are also the first to be published in Nature Medicine with Chinese researchers as the first and corresponding authors of a novel mechanism for treatment of diabetes. Both studies demonstrated that by addressing the defect of the glucose sensor function of glucokinase (GK), dorzagliatin is able to continuously and effectively reduce HbA1c in patients with T2D, and significantly reduce post-meal glucose (2h-PPG) during the treatment period. The percentage of patients admninistered dorzagliatin achieving standard glycemic blood glucose control was demonstrated to be high and with low hypoglycemia incidences. It was also shown that dorzagliatin has good safety and tolerability. In addition, it can continuously improve beta-cell function and reduce insulin resistance.

Dorzagliatin is the first-in-class oral drug developed by Hua Medicine for the treatment of T2D after 10 years of independent research and development, which identifies GK as a therapeutic target. GK plays a critical role in maintaining blood glucose homeostasis in human body, serving as a glucose sensor to sense changes of the blood glucose, and timely stimulates glucose control organs to secrete insulin, GLP-1 or glucagon, so as to effectively regulate blood glucose level and maintain blood glucose homeostasis (4-6.5 mmol/L). Impaired sensitivity of glucose, mainly manifested as impaired glucose stimulated insulin secretion (GSIS) function of pancreatic beta-cells and rise of FPG level blood sugar fluctuations, is the root cause of T2D. Dorzagliatin can act on GK in glucose control organs such as pancreas, liver and intestine. By restoring GK activity in T2D patients, it helps restore the sensitivity of the human body to blood glucose changes, and thus improves the early phase insulin secretion and beta-cell function. In this way, blood glucose homeostasis can be rebuilt to control or delay the progression of T2D, and fundamentally treat diabetes and discontinue medication. Hua Medicine has published over 10 papers on the results of basic and clinical studies to continually elaborate its scientific concept of "restoring sensitivity, rebuilding homeostasis, and treating diabetes at its source". The results of the Phase III trial published by Nature Medicine are the clinical validation of this innovative concept. In March 2021, Hua Medicine submitted the new drug application (NDA) of dorzagliatin to the China National Medical Products Administration (NMPA) for T2D treatment, which was accepted in April. Currently, the NDA of dorzagliatin is under active review by the NMPA. Hua Medicine is fully supporting this process to obtain the approval of dorzagliatin as early as possible.

Nature Medicine is a top journal, focusing on the field of biomedicine. It mainly publishes original research papers that "demonstrate novel insight into disease processes, with direct evidence of the physiological relevance of the results", and has begun to focus on publishing papers of large clinical research in recent years. The impact factor of Nature Medicine has been on the rise. With a 2-year impact factor of 53.44, it has surpassed Nature to be one of the top five medical journals, also including The New England Journal of Medicine (NEJM), The Lancet, The Journal of the American Medical Association (JAMA) and The British Medical Journal (BMJ), known traditionally as four medical journals. Since 2009, Franz Matschinsky, the father of GK, first reported the research and development of GKA in Nature Reviews Drug Discovery, the theoretical research and drug research and development results related to GKA have drawn worldwide attention, and have been highly valued by the international academic and clinical medical communities. Before, the results of the Phase II clinical trial of dorzagliatin were published in the advanced medical journal The Lancet Diabetes and Endocrinology. Since 2014, Hua Medicine has been presenting the results of basic researches and clinical studies of dorzagliatin at the world's largest and most important diabetes conference - the American Diabetes Association (ADA) Scientific Sessions every year. It was through the ADA Scientific Sessions that the editors of Nature Medicine noticed the innovativeness and breakthrough nature of dorzagliatin, and took the initiative to make an appointment with Hua Medicine for scripts. These two newly published papers present the Phase III results of the SEED study and the DAWN study of dorzagliatin, respectively.

The SEED study is a study of dorzagliatin monotherapy. It is a randomized, double-blind and placebo-controlled Phase III registered clinical study in drug naive T2D patients. The study was conducted among 463 T2D patients. The first 24 weeks were randomized, double-blind and placebo-controlled treatment, designed to evaluate the primary efficacy and safety endpoints of dorzagliatin. The subsequent 28 weeks were open-label period for dorzagliatin, designed to continuously observe and evaluate the safety of dorzagliatin. The SEED study was led by Professor Dalong Zhu, the President of the Chinese Diabetes Society, and Director of Medical Center for Endocrine and Metabolic Diseases of Gulou Hospital, affiliated to Medical College of Nanjing University. This study showed that dorzagliatin can effectively reduce the blood glucose of drug naive T2D patients, with good safety and tolerability. The main conclusions of the SEED study include:

Significant and long-lasting efficacy:
-- There was a 1.07% HbA1c reduction from baseline in 24 weeks, significantly better than that of the placebo treated group (p<0.001)
-- The standard-reaching rate of HbA1c was 42.5% in 24 weeks, significantly higher than that of the placebo treated group (p<0.001)
-- Significantly improved beta cell function, with a 3.28 increase in HOMA2-beta in 24 weeks compared with the placebo treated group
-- The 2h-PPG observably decreased by 2.33mmol/L compared with the placebo treated group in 24 weeks
-- The FPG observably decreased by 0.33mmol/L compared with the placebo treated group in 24 weeks
-- The HbA1c continued to remain steady in 52 weeks

Good tolerability and safety:
-- The hypoglycemia (<3mmol/L) incidence rate was less than 1% in 24 weeks, and there was no severe hypoglycemia reported
-- The hypoglycemia (<3mmol/L) incidence rate was less than 1% in 52 weeks, and there was no severe hypoglycemia reported
-- In 52 weeks, there was no drug-related SAE

The DAWN study is a randomized, double-blind, placebo-controlled Phase III study among 767 patients, which uses dorzagliatin combined with metformin to treat T2D patients who failed in metformin adequacy therapy. The first 24 weeks were randomized, double-blind and placebo-controlled treatment, designed to evaluate the primary efficacy and safety endpoints of dorzagliatin. The subsequent 28 weeks were open-label period for dorzagliatin, designed to continuously observe and evaluate the safety of dorzagliatin. The DAWN study was led by Professor Wenying Yang at China-Japan Friendship Hospital, who is the former President of the Chinese Diabetes Society and present Vice President of the Asian Diabetes Association. This study showed that dorzagliatin can effectively reduce the blood glucose of T2D patients who failed in metformin adequacy therapy, with good safety and tolerability. The main conclusions of the DAWN study include:

Significant and long-lasting efficacy:
-- The HbA1c reduction was 1.02% from baseline, significantly better than that of the placebo treated group in 24 weeks
-- The standard-reaching rate of HbA1c was 44.4% in 24 weeks, significantly higher than 10.7%(p<0.0001) in the placebo treated group
-- Significantly improved beta cell function and HOMA2-beta increased by 2.43 compared with the placebo treated group in 24 weeks
-- The 2h-PPG observably decreased by 2.48mmol/L compared with the placebo treated group in 24 weeks
-- The FPG observably decreased by 0.38mmol/L compared with the placebo treated group in 24 weeks
-- The HbA1c continued to remain steady in 52 weeks

Good tolerability and safety:
-- The hypoglycemia (<3mmol/L) incidence rate is less than 1% in 24 weeks, and there was no severe hypoglycemia reported
-- The hypoglycemia (<3mmol/L) incidence was less than 1% in 52 weeks, and there was no severe hypoglycemia reported
-- In 52 weeks, there was no drug-related SAE

Professor Dalong Zhu, the first author of the paper on SEED, said, "The investigator team of dorzagliatin and the R&D team of Hua Medicine have always focused on the clinical needs of patients and adhered to scientific rigor to successfully develop this first-in-class new drug together. The publication of the results of the two Phase III clinical studies on Nature Medicine is another proof of the international academic community recognizing China's new drug development capabilities. As a clinical investigator, I feel very proud and confident about the future of innovative drug development in China. In clinical trials, dorzagliatin has demonstrated long-lasting and stable efficacy, as well as good safety and tolerability. In the meanwhile, it showed significant potentiation in combination trials with SGLT-2 inhibitors and DPP-4 inhibitors. I am very much looking forward to bringing new treatment options with dorzagliatin to Chinese T2D patients soon."

Professor Xiaoying Li, the co-corresponding author of the paper and Director of the Department of Endocrinology at Zhongshan Hospital affiliated to Fudan University, said, "Nature Medicine is a top journal with a high impact factor. The clinical trial of dorzagliatin is designed in line with the standards of international multinational companies. All the investigators and developers followed a high bar of standards and quality, which led to the creation of such a high-value breakthrough drug. I'm very proud and excited about this achievement. Type 2 diabetes is a critical threat to human health. As clinicians, our involvement in the clinical development of dorzagliatin has given us the opportunity to review the regulating mechanisms of glucose homeostasis and to better understand the process and characteristics of the progression of type 2 diabetes. "

Professor Wenying Yang, the first author of the DAWN paper, said, "I am very excited and happy! Before, the results of Phase II clinical study of dorzagliatin were published in The Lancet Diabetes and Endocrinology, and now the results of Phase III clinical study were published in Nature Medicine. Such achievements are completely on par with the first-in-class diabetes drugs developed by multinational pharmaceutical companies. This is a great recognition on Chinese innovative drugs, the best return to Hua Medicine and Dr. Chen Li's 10 years of hard work, and the most memorable experience for us as clinical investigators. We are fortunate to meet such a good pioneer. I look forward to the launch of dorzagliatin soon!"

Dr. Yi Zhang, Chief Medical Officer, Senior Vice President of Pharma Development of Hua Medicine and the head of clinical development for dorzagliatin, said, "The publication of the results of the two clinical studies, i.e., the SEED study and the DAWN study, on Nature Medicine fully demonstrated the scientific research capabilities of Chinese clinical researchers and Hua Medicine's innovative R&D strengths as a China-based biopharmaceutical company. The Phase III clinical trial of dorzagliatin is the first confirmatory clinical study of GKA drugs completed worldwide. It is also the first clinical trial of a first-in-class investigational diabetes drug led by a Chinese clinical team with Chinese subjects as the research objects. We are very grateful to all clinical researchers for their unremitting efforts and hard work. In the future, Hua Medicine is confident to join hands with partners in various clinical fields to make new breakthroughs in the field of Type 2 diabetes and the whole metabolic diseases."

Dr. Li Chen, Founder, CEO, Chief Scientific Officer of Hua Medicine and corresponding author of both papers, said, "We are very pleased to collaborate with Jennifer Sargent, Editor-in-Chief, to publish the clinical research results of dorzagliatin in Nature Medicine. This illustrates the strong interest and attention of the international medical community on the GK mechanism and GKA drugs. In 1968, Professor Franz Matschinsky, the father of glucokinase, discovered the critical role of GK in glucose-stimulated insulin secretion and proposed glucokinase as a diabetes gene and glucose sensor. The drug development of glucokinase activators has, since then, undergone numerous difficulties and failures. More than 50 years later, I am very pleased to see that Hua Medicine R&D team and Chinese clinical experts, after ten years of hard work, have overcome many R&D difficulties and greatly improved the understanding of glucokinase's role in the regulation of blood glucose homeostasis and diabetes treatment, established the world's leading scientific concept of diabetes treatment, and successfully transformed it into the breakthrough new drug dorzagliatin. The recently results of the DREAM study, further elucidates that dorzagliatin can fundamentally treat T2D and achieve diabetes remission without any glucose-lowering medication after the completion of the SEED study. Hua Medicine is proactively supporting the NMPA approval process to bring this innovative drug to the benefit of Chinese type 2 diabetes patients as soon as possible."

Design of the SEED study
The SEED study is a randomized, double-blind and placebo-controlled Phase III study conducted in 463 drug naive T2D patients. The whole study lasted for 53 weeks, including 52 weeks of treatment and 1 week of safety follow-up. The first 24 weeks were randomized, double-blind and placebo-controlled to assess the efficacy and safety of dorzagliatin. Patients were treated with twice-daily doses of dorzagliatin (75mg) or placebo, randomized 2:1. The subsequent 28-week were the open-label treatment period, during which all subjects were treated with twice-daily doses of dorzagliatin (75mg). The study was conducted at 40 clinical sites across China led by Professor Dalong Zhu, the President of the Chinese Diabetes Society, Director of Medical Center for Endocrine and Metabolic Diseases of Gulou Hospital, affiliated to Medical College of Nanjing University. (Clinical study registration number: NCT03173391)

Design of the DAWN study
The DAWN study is a randomized, double-blind, placebo-controlled Phase III study in 767 Type 2 diabetes patients, which uses dorzagliatin combined with metformin to treat patients who failed in metformin adequacy therapy. During the first 24 weeks of double-blinded treatment, subjects were treated with metformin (Glucophage) at 1,500mg/day as the basic therapy, and they were given twice-daily doses of dorzagliatin (75mg) or placebo, randomized on a 1:1 ratio. During the subsequent 28-week open-label treatment period, all subjects received dorzagliatin 75mg twice daily and 1500mg/day of metformin (Glucophage). The trial was conducted in 72 clinical sites across China led by Professor Wenying Yang of China-Japan Friendship Hospital, the former President of the Chinese Diabetes Society and present Vice President of the Asian Diabetes Association. (Clinical study registration number: NCT03141073)

About Dorzagliatin
Dorzagliatin is an investigational first-in-class, dual-acting glucokinase activator, designed to control the progressive and degenerative nature of diabetes by restoring glucose homeostasis in patients with Type 2 diabetes. By fixing the defect of the glucose sensor function of glucokinase, dorzagliatin has the potential to restore the impaired insulin and GLP-1 secretion of patients with Type 2 diabetes and serve as a cornerstone therapy targeting the root cause of the disease. Two Phase III registered trials for dorzagliatin monotherapy and the combination of dorzagliatin and metformin respectively have been completed in China, as well as the studies on drug mechanism synergy with sitagliptin (DPP-4 inhibitor) and empagliflozin (SGLT-2 inhibitor). In an investigator-initiated study named as DREAM, a 65.2% diabetes remission rate was observed without any antidiabetes medication during the 52-week study period. The Company has obtained the "Drug Manufacturing Permit" of dorzagliatin issued by the Shanghai Municipal Drug Administrative Bureau, and has submitted its NDA to the National Medical Products Administration in order to realize the "First in Global, Start from China" mission for the benefits of diabetic patients worldwide.

About Hua Medicine

Hua Medicine is an innovative drug development company in China focused on developing novel therapies for patients worldwide with unmet medical needs. Hua Medicine teams up with global high caliber people and integrates global resources to explore breakthrough technologies and products and accelerate global innovation in diabetes care. Targeting the glucose sensor glucokinase, dorzagliatin, a novel oral diabetes drug restoring glucose sensitivity in T2D patients, has completed SEED and DAWN registration trials, and filed NDA in China. This global first-in-class glucokinase activator (GKA) has demonstrated its potential of achieving diabetes remission to help millions of diabetic patients around the world.

For more information
Hua Medicine
Website: www.huamedicine.com

Investors
Email: ir@huamedicine.com

Media
Email: pr@huamedicine.com


Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.com

source https://www.acnnewswire.com/press-release/english/75175/

NEC、SISと共に提供する為替BPOサービスが全国44信用金庫1033店舗で稼働

TOKYO, May 13, 2022 - (JCN Newswire) - NECは、2021年3月より株式会社しんきん情報サービス(本社:東京都港区、代表取締役社長:馬場 英一 以下、SIS)と協業し、自動化機能を備えた為替BPOサービス(注1)を提供しています。順次展開を始めており、城北信用金庫や巣鴨信用金庫、さわやか信用金庫、北上信用金庫、熊本中央信用金庫などBPOサービスの新規加入を含めた全国44信用金庫1,033店舗で稼働を開始し、2023年3月には84信用金庫2,100店舗での稼働を予定しています。

本サービスは、特性の異なる2つのOCR(注2)を用いて手書きの振込依頼書の文字を読み取り、金融業界では初めてシステム入力までを自動化する機能(特許出願中)を備えており、人を介す機会を減らすことで⼈為ミスの削減と事務作業の効率化を実現しております。

現在稼働している1,033店舗からは、月間47万件、ピーク時には1日6万件の振込依頼を受け付けており、登録式連記帳票では70%以上、全体でも約60%を自動で処理することで、トータルコストの削減を実現しております。今後、自動処理機能の性能を高めながら年間1,000万件の為替振込処理に対応していく予定です。

これまでNECやSISのそれぞれの既存ユーザの移行を中心に対応してきましたが、今月より未加入の信用金庫の利用に向け準備を開始すると共に、地方銀行などさまざまな金融機関への拡大を目指します。また環境負荷の軽減にも取り組んでおり、BPOセンターに集約することによるサーバやPCの効率的な運用や、自動処理を推進することによるPC稼働率の抑制で消費電力を削減するなど、持続可能な社会の実現とSDGsの達成に貢献します。

背景

金融業界では、膨大なバックオフィス業務に正確性とスピードが求められ、ICTを活用したデジタル化による業務改革の推進が喫緊の課題となっています。そうした中、NECとSISは、NECのデジタル技術および多くの金融機関でのバックオフィス業務システム構築実績と、SISの多くの信用金庫への為替集中サービス導入実績・ノウハウ、それぞれの強みとスケールメリットを活かし、為替振込の自動処理機能を備えた新たなBPOサービスを開発しました。

サービス概要

本サービスは、手書きの振込依頼書を特性が異なる2つのOCRエンジンで読み取り、さらに振込先などの過去の取引データを自動で参照(注3)することで、判別しにくい文字の読み取りを補助します。また、振込金額や振込指定日など、過去の実績を参照できない情報については、NECとSISが共同で出願済みの特許を用いて、2つのOCRエンジンが読み取った結果を独自の方法で相関チェックし、誤読を防止した上で自動発信処理を実行します。機械が判定できない項目のみ人手で入力し、効率化した作業で業務全体を支えます。今後、AIを用いて制定帳票だけではなく私製帳票にも対応した自動処理機能を実装していく予定です。

NECは、AIをはじめとする先進技術を活用し、安全で快適な金融サービスを、あらゆる人と産業へ届けるための取り組みを推進します。これにより、人やモノ、プロセスの情報・状態をバリューチェーン全体で共有し、新たな価値を生み出す「NEC Value Chain Innovation」(注4)をお客さまと共に実現していきます。

本リリースの詳細は下記をご参照ください。
https://jpn.nec.com/press/202205/20220513_01.html

概要:日本電気株式会社(NEC)

詳細は www.nec.co.jp をご覧ください。


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/yXd4oJ6

Soluna Raises $35M from Spring Lane Capital to Build Green Data Centers for Crypto, Machine Learning

ALBANY, NY, May 12, 2022 - (ACN Newswire) - Soluna Holdings, Inc. ("SHI" or the "Company"), (NASDAQ: SLNH), the parent company of Soluna Computing, Inc. ("SCI"), secured $35 million in project financing to develop green data centers co-located with renewable energy assets. Spring Lane Capital, a private equity firm, invested private funds in Soluna as a part of their strategy focused on hybrid project capital for sustainability solutions in the energy, food, water, waste and transportation industries. The capital will help develop three behind-the-meter (BTM) projects designed to convert wasted renewable energy into clean computing services such as bitcoin mining and artificial intelligence.

"Soluna is the only true green bitcoin company we've yet seen," said Rob Day, Spring Lane Capital Partner and Co-Founder. "Going after wasted renewable energy 'spilled power' is a compelling solution and fixes both bitcoin's climate problem and wind power's grid problem."

Michael Toporek, CEO of Soluna Holdings, Inc. said, "Consistent with our previously articulated strategy, we continue to pursue opportunities that we believe enable us to optimize our cost of capital. The Spring Lane Capital approach helps us develop a mature repeatable model that can be scaled."

The first of the three projects, Dorothy, named in honor of African American mathematician and human computer Dorothy Vaughan, is expected to be energized later this summer and coincide with the launch of a local STEM program. The Dorothy project is a 100 MW data center with a 50 MW initial phase, connected to a Texas wind farm that produces more electricity than the grid can consume. Soluna's data center is currently estimated to create between 25 to 50 highly skilled jobs for technicians, security and electrical staff.

The other two projects funded by the new capital will come from Soluna's robust pipeline.

John Belizaire, CEO of Soluna Computing, Inc., said, "We are honored to have a pioneering sustainability project finance firm like Spring Lane Capital back our vision. Our model of leveraging excess clean energy to generate low-cost computing is the future of green bitcoin mining and green data centers."

Spring Lane Capital has a successful track record helping sustainable technology companies raise capital to build flagship projects. Their 'hybrid project capital' approach provides project equity along with additional growth capital.

Added Day: "Soluna is driving demand for clean power by giving a floor price and improving the bottom line of the renewable power partners they work with. The ultimate result is more wind farms and solar farms that would not otherwise be built."

At power plants like the wind farm where the Dorothy project is under construction, excess energy is wasted when the grid becomes overloaded or demand is too low. Soluna's scalable solution allows every excess megawatt to be used for batch-oriented, computing-intensive processes, such as cryptocurrency mining and machine learning. Additionally, flexible demand consumers help stabilize the grid by preventing power overload, which can otherwise lead to blackouts and grid malfunction.

Last month, Soluna Holdings (SCI's Computing's parent company), sold its Albany-based MTI Instruments subsidiary for $10.75 million, expanding its focus on helping the modern grid absorb more renewable energy through flexible green data centers.

About Soluna Holdings, Inc.

Soluna Holdings, Inc. (Nasdaq: SLNH), which operates through its subsidiary, Soluna Computing, Inc. is the leading developer of green data centers that convert excess renewable energy into global computing resources. Soluna builds modular, scalable data centers for computing-intensive, batchable applications such as cryptocurrency mining, AI and machine learning. Soluna provides a cost-effective alternative to battery storage or transmission lines. Up to 30% of the power of renewable energy projects can go to waste. Soluna's data centers enable clean electricity asset owners to 'Sell. Every. Megawatt.' For more information about Soluna, please visit solunacomputing.com or follow us on LinkedIn and Twitter.

Investor Relations:
Kirin Smith, President
PCG Advisory, Inc.
646.823.8656
Ksmith@pcgadvisory.com

Media contact:
Bridgette Borst Ombres, Tigercomm
(304) 546-3788
bombres@tigercomm.us

Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.com

source https://www.acnnewswire.com/press-release/english/75141/

Soluna Raises $35M from Spring Lane Capital to Build Green Data Centers for Crypto, Machine Learning

ALBANY, NY, May 12, 2022 - (JCN Newswire) - Soluna Holdings, Inc. ("SHI" or the "Company"), (NASDAQ: SLNH), the parent company of Soluna Computing, Inc. ("SCI"), secured $35 million in project financing to develop green data centers co-located with renewable energy assets. Spring Lane Capital, a private equity firm, invested private funds in Soluna as a part of their strategy focused on hybrid project capital for sustainability solutions in the energy, food, water, waste and transportation industries. The capital will help develop three behind-the-meter (BTM) projects designed to convert wasted renewable energy into clean computing services such as bitcoin mining and artificial intelligence.

"Soluna is the only true green bitcoin company we've yet seen," said Rob Day, Spring Lane Capital Partner and Co-Founder. "Going after wasted renewable energy 'spilled power' is a compelling solution and fixes both bitcoin's climate problem and wind power's grid problem."

Michael Toporek, CEO of Soluna Holdings, Inc. said, "Consistent with our previously articulated strategy, we continue to pursue opportunities that we believe enable us to optimize our cost of capital. The Spring Lane Capital approach helps us develop a mature repeatable model that can be scaled."

The first of the three projects, Dorothy, named in honor of African American mathematician and human computer Dorothy Vaughan, is expected to be energized later this summer and coincide with the launch of a local STEM program. The Dorothy project is a 100 MW data center with a 50 MW initial phase, connected to a Texas wind farm that produces more electricity than the grid can consume. Soluna's data center is currently estimated to create between 25 to 50 highly skilled jobs for technicians, security and electrical staff.

The other two projects funded by the new capital will come from Soluna's robust pipeline.

John Belizaire, CEO of Soluna Computing, Inc., said, "We are honored to have a pioneering sustainability project finance firm like Spring Lane Capital back our vision. Our model of leveraging excess clean energy to generate low-cost computing is the future of green bitcoin mining and green data centers."

Spring Lane Capital has a successful track record helping sustainable technology companies raise capital to build flagship projects. Their 'hybrid project capital' approach provides project equity along with additional growth capital.

Added Day: "Soluna is driving demand for clean power by giving a floor price and improving the bottom line of the renewable power partners they work with. The ultimate result is more wind farms and solar farms that would not otherwise be built."

At power plants like the wind farm where the Dorothy project is under construction, excess energy is wasted when the grid becomes overloaded or demand is too low. Soluna's scalable solution allows every excess megawatt to be used for batch-oriented, computing-intensive processes, such as cryptocurrency mining and machine learning. Additionally, flexible demand consumers help stabilize the grid by preventing power overload, which can otherwise lead to blackouts and grid malfunction.

Last month, Soluna Holdings (SCI's Computing's parent company), sold its Albany-based MTI Instruments subsidiary for $10.75 million, expanding its focus on helping the modern grid absorb more renewable energy through flexible green data centers.

About Soluna Holdings, Inc.

Soluna Holdings, Inc. (Nasdaq: SLNH), which operates through its subsidiary, Soluna Computing, Inc. is the leading developer of green data centers that convert excess renewable energy into global computing resources. Soluna builds modular, scalable data centers for computing-intensive, batchable applications such as cryptocurrency mining, AI and machine learning. Soluna provides a cost-effective alternative to battery storage or transmission lines. Up to 30% of the power of renewable energy projects can go to waste. Soluna's data centers enable clean electricity asset owners to 'Sell. Every. Megawatt.' For more information about Soluna, please visit solunacomputing.com or follow us on LinkedIn and Twitter.

Investor Relations:
Kirin Smith, President
PCG Advisory, Inc.
646.823.8656
Ksmith@pcgadvisory.com

Media contact:
Bridgette Borst Ombres, Tigercomm
(304) 546-3788
bombres@tigercomm.us


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/yXd4oJ6

Mitrade wins two esteemed awards at Forex Broker Award 2022

MELBOURNE, May 12, 2022 - (ACN Newswire) - Australian Forex and OTC derivatives trading broker Mitrade has received two esteemed awards by FxDailyInfo at the Forex Broker Award 2022.

Mitrade wins two esteemed awards at Forex Broker Award 2022

Mitrade has been crowned the Most Innovative Broker 2022 and the Best Trading Platform 2022. The awards are given by FxDailyInfo, which rewards Forex brokers for consistent innovation and intuitive trading platforms. To declare winners, FxDailyInfo also takes into account several key factors including ground-breaking technology, cross-platform compatibility, responsive customer service, risk management, and fast growth.

"We are profoundly humbled to receive these distinguished awards. We take this double win as a recognition of our hard work and commitment to make trading easy for all. This milestone is an inspirational motivation for our team, that we are on the right track. This achievement has encouraged our team to bring even more innovation to our trading system and make Mitrade a leading Forex trading platform. Our team strives to make our trading platform more intuitive in the future," said a representative of Mitrade.

Mitrade went through a massive structural overhaul of its team and resources in 2019. It introduced a proprietary web trading platform, which immediately started gaining worldwide attention and engagement due to its simple user interface and smooth function. Later on, the innovative WebTrader was complemented by mobile apps for Google Play and iOS. The mobile apps brought cross-platform compatibility to Mitrade, making trading on the go possible for everyone.

Earlier this year, Mitrade also bagged four 2022 awards from International Business Magazine -- Most Trusted Broker Asia, Best Forex Educational Resources Global, Most Transparent Forex Broker Global and Best Trading Platform Australia.

Continuing its innovation streak, Mitrade has recently upgraded its mobile app with cutting edge features. The app now comes with a built-in economic event calendar that lets traders forecast market trends and craft a winning trading strategy ahead of potential market movements. The mobile app also has a tiered trading educational portal, which guides both beginners and experts.

This innovative spirit has won Mitrade many prestigious awards and added to its immense popularity among the global trading community. Mitrade's evolving technology, dynamic research tools, and instant-response 24/7 customer service fueled its growth to over 1,100,000 customers in a short span of three years. The Mitrade app on Google Play has surpassed 1 million downloads.

In addition, Mitrade has also won the Most Innovative Forex Fintech Broker 2021 by Global Brands Magazine and Best Mobile Trading Platform 2020 by Forex Awards. More information can be found at www.mitrade.com/about-us/awards.

For media inquiries, please contact Ms Belle Toh at belle.toh@mitrade.com.

About Mitrade
Mitrade is an innovative financial technology group and Forex trading leader. It operates under strict regulations by the Mauritius Financial Services Commission (FSC), Australian Securities and Investments Commission (ASIC) and the Cayman Islands Monetary Authority (CIMA). Mitrade was founded by technology experts and finance veterans who had a mission to simplify trading through consistent innovation. With its self-developed proprietary trading platform, Mitrade is pursuing its mission to provide simplified trading to all. Explore Mitrade at www.mitrade.com.

Mitrade's OTC derivatives trading contains leverage which can cause the loss of your entire capital.


Source: Mitrade Holding Ltd

Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.com

source https://www.acnnewswire.com/press-release/english/75110/

SGシステム・佐川グローバルロジスティクス・NEC、協調搬送ロボット導入に向けて実証実験を実施

TOKYO, May 12, 2022 - (JCN Newswire) - SGシステム株式会社(本社:京都府京都市、代表取締役社長:谷口友彦、以下SGS)および佐川グローバルロジスティクス株式会社(本社:東京都品川区、代表取締役社長:山本将典、以下SGL)並びに日本電気株式会社(本社:東京都港区、代表取締役 執行役員社長 兼CEO:森田 隆之、以下NEC)は、SGホールディングスグループの次世代型大規模物流センター「Xフロンティア」内の通販専用のプラットフォーム「EC Logi Tokyo」(所在地:東京都江東区)への協調搬送ロボット導入に向け、実証実験を行います。

本実証実験は、NECの協調搬送ロボットを活用したソリューション(注1)による入出荷作業の生産性向上を検証するもので、今後3社は本実証実験に基づき「EC Logi Tokyo」への本格導入を目指します。

物流業界では慢性的な人手不足が続く一方で、旺盛なEC需要に伴う荷物の増加により、生産性の向上が求められています。特に近年では多様な荷姿への対応、物量の増減や新設備導入に伴う倉庫内スペースのレイアウト変更、深夜時間帯の作業員の確保などが喫緊の課題となっています。

今回の実証実験で活用する協調搬送ロボットは、2台のロボットでユニットロード(カゴ車、平台車等の荷物搬送機器)を挟み込む形で搬送を行います。これにより、ユニットロードの大きさや形状にかかわらず、搬送時にロボットに固定する治具などが不要となり、作業員のサポートなしに自動搬送することが可能です。また本ソリューションでは、倉庫に設置したカメラから得られる情報を集約し複数ロボットを一括して制御を行うため、搬送ルートの指定やレイアウト変更への対応などを容易に行うことが可能です。

今回の実証実験では、「EC Logi Tokyo」内に設定された約50メートルのルートを使用し、協調搬送ロボットを用いて20種類以上の大きさや形状の異なる荷物の搬送を行います。多様な形状の荷物を作業員のサポートなしに、所定のルートを自動搬送する作業を行い、本搬送方式の有用性を検証します。また、実際の入出荷作業を想定し、作業員の事務作業などと連携した搬送を行うことで、本格導入時の生産性の向上を検証します。

SGSは今後、NECと共に今回の実証実験で使用した協調搬送ロボットの展開・導入を行ってまいります。加えて、今回の実証実験で得た知見を活かし、物流自動化ソリューション(注2)の更なる強化に取り組み、物流業界全体の課題解決に貢献してまいります。

SGLは、物流課題の解決に向けこれからも様々なロボティクスの導入を進め、これまで蓄積したノウハウを活用することによる生産性の向上に加え、新たなソリューションを提案できるようDXを推進し、お客さまの経営課題に物流を通じて最適解を提案してまいります。

NECは、SGSとSGLとの本実証で得られた知見を加え、今後も協調搬送ロボットのさらなるUX(ユーザーエクスペリエンス)向上に取り組み、省人化・生産性の向上といった物流業界における課題解決ソリューションを社会に実装し貢献してまいります。

本リリースの詳細は下記をご参照ください。
https://jpn.nec.com/press/202205/20220512_01.html

概要:日本電気株式会社(NEC)

詳細は www.nec.co.jp をご覧ください。


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/yXd4oJ6

Q&M Dental net profit, excluding other gains or losses, increased by 25% to S$7.2 million on S$46.8 million of revenue for quarter ended 31 March 2022

SINGAPORE, May 12, 2022 - (JCN Newswire) - Q&M Dental Group (Singapore) Limited, a leading private dental healthcare group in Asia, reported net profit excluding other gains or losses attributable to shareholders of S$7.2 million for the quarter ended 31 March 2022 (1Q2022) compared to S$5.8 million in the corresponding period (1Q2021).

Dr Ng Chin Siau, Chief Executive Officer of Q&M Dental said, "We are heartened by our continuous strong performance in 1Q2022 following a record-setting year FY2021. Our core dental business will remain strong, and with the abolishing of most of the pandemic restrictions, a positive impact on the economy, we are looking forward to resuming our growth trajectory of expanding our network of clinics in the coming quarters."

Growth & Expansion in Operations

As at 31 March 2022, the Group's number of dental outlets in Singapore has grown to 99, from 85 as at 31 March 2021. Similarly in Malaysia, the number of dental outlets has increased to 41, as compared to 36 previously.

The Group also continues to focus on its expansion into medical diagnostics, with its associated Company, Aoxin Q&M Dental Group Limited and through its recent acquisition of 49% shareholding of Acumen Diagnostics Pte. Ltd., raising Q&M's effective interest in Acumen Diagnostics from 51% to 67%. In the near term, Acumen Diagnostics' clinical testing laboratory will roll out its pipeline of new tests, including PCR assays for dengue, sepsis and, identification of bacterial pathogens and their associated antibiotics resistance in pneumonia and bloodstream infections. Its longer-term plans include the development of new vaccines.

For 1Q2022, revenue contribution from dental and medical clinics was relatively unchanged with a marginal decrease of 2% to S$38.6 million, despite the challenges of the tightening of Safe Management Measures (SMM) due to the rapid spread of the Omicron variant. Revenue contribution from medical laboratory and dental equipment & supplies segment surged by 80% to S$8.2 million on the back of increased revenue from Covid-19 testing from Acumen Diagnostics, the Group's medical laboratory business, which obtained its medical laboratory license in September 2020.

The Group's net profit after tax excluding other gains or losses for 1Q2022 increased by 25% to S$7.2 million, from S$5.8 million in the corresponding period last year, translating to an earnings per share of 0.69 Singapore cent.

As at 31 March 2022, the Group had cash and cash equivalents of S$43.5 million with net assets of S$94.9 million. This translates to Net Asset Value per share of 10.10 cents per share.

Outlook & Further Expansion Plans

With the opening up of the Singapore economy gathering pace in 2022, the country expects to see businesses ramping up in most sectors with those that were most severely affected by the pandemic like F&B, tourism to especially benefit. The government is forecasting GDP growth of between 3.0 to 5.0% in 2022, Barring any major changes in the global macroeconomic and political situation or any new adverse developments in the evolving Covid-19 situation, the Group is cautiously optimistic on its business outlook.
The Group intends to continue executing the business plans outlined below:

- Expansion of network of dental clinics in Singapore and Malaysia

The Group currently operates 99 clinics in Singapore. With the economy opening up in 2022, the Group will also intensively increase its reach through organic growth of its dental clinic network in Singapore. This will be supported by an expansion of its team of dentists to undergird the future growth of its operations in Singapore. We will continue to develop, invest and optimise our digital Artificial Intelligence (AI) guided clinical decision support system to provide the most effective and suitable treatment plans for patients. The Group believes it is well-positioned to cater to the rising demand for primary and high-value specialist dental healthcare services of its patients.

Currently, the Group operates 41 clinics in Malaysia. The clinics are located in Johor (16 dental clinics), Kuala Lumpur (9 dental clinics), Selangor (11 dental clinics), Melaka (4 dental clinics) and 1 dental clinic in Negeri Sembilan.

The Group intends to open at least 30 dental clinics a year from 2021 onwards in Singapore and Malaysia for the next 10 years. The eventual number of dental outlets will depend on available opportunities, pertinent market conditions and the evolving Covid-19 situation.

- Expansion into private dental healthcare market in the People's Republic of China ("PRC")

The main thrust of the Group's proposed expansion in PRC is through organic growth to develop a new and sustainable growth pillar that can yield long term value for the Group.

- Expansion in Southeast Asia

The Group is continuously looking out for strategic opportunities to expand its dental business and regional footprint to other Southeast Asian countries.

- Medical Laboratory

The Group will focus on rolling out its clinical testing laboratory pipeline of new tests including PCR assays for dengue sepsis and identification of bacterial pathogens and their associated antibiotics resistance in pneumonia and bloodstream infections.

Please see links for PDF documents from SGXNET.
Results: https://tinyurl.com/QnM-1Q2022-Result
Press Release: https://tinyurl.com/QnM-1Q-2022-Release

About Q&M Dental Group (Singapore) Limited (QC7.SI)

Q&M Dental Group (Singapore) Limited (QC7.SI) ("Q&M" or together with its subsidiaries, the "Group") is a leading private dental healthcare group in Asia.

The Group owns the largest network of private dental outlets in Singapore, operating 99 dental outlets across the country. Underpinned by about 290 experienced dentists and over 350 supporting staff, the Group sees an average of 40,000 patient visits a month in Singapore. The Group also operates 5 medical clinics and a dental supplies and equipment distribution company.

Outside of Singapore, the Group has 41 dental clinics and a dental supplies and equipment distribution company in Malaysia, as well as a dental clinic in the People's Republic of China ("PRC"). Q&M is also the substantial shareholder of Aoxin Q&M Dental Group Limited, a dental Group listed on the Catalist board of the Singapore Exchange that operates dental clinics and hospitals primarily in the north- eastern region of the PRC. The Group aims to expand its operations geographically and vertically through the value chain in Malaysia, the PRC and within the ASEAN region.

The Q&M College of Dentistry was established in 2019 to offer postgraduate dental education as part of its commitment to continual education and professional development of dentists. It offers Singapore's first private postgraduate diploma programme in clinical dentistry.

In 2020, the Group expanded into the medical laboratories and research industry with the strategic investment into Acumen Diagnostics Pte. Ltd. ("Acumen"). Acumen currently focuses on the manufacture, sale and distribution of COVID-19 diagnostic test kits, as well as COVID-19 testing. It is also working to roll out a pipeline of new tests, including PCR assays for dengue, sepsis and, identification of bacterial pathogens and their associated antibiotics resistance in pneumonia and bloodstream infections.

EM2AI Pte Ltd, a wholly-owned subsidiary of the Group that focuses on developing AI-powered solutions to diagnosis and treatment planning has rolled out IDMS, enabling dentists within the Group's network to administer ethical treatment plans for patients.

The Group was listed on the Mainboard of the Singapore Exchange Securities Trading Limited ("SGX- ST") on 26 November 2009. For more information on the Group, please visit www.QandMDental.com.sg

For more information, please contact:
Waterbrooks Consultants Pte Ltd
Wayne Koo
Tel: +65 9338-8166
Email: wayne.koo@waterbrooks.com.sg

Derek Yeo
Tel: +65 9791-4707
Email: derek@waterbrooks.com.sg


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/Aaepd8I

Q&M Dental net profit, excluding other gains or losses, increased by 25% to S$7.2 million on S$46.8 million of revenue for quarter ended 31 March 2022

SINGAPORE, May 12, 2022 - (ACN Newswire) - Q&M Dental Group (Singapore) Limited, a leading private dental healthcare group in Asia, reported net profit excluding other gains or losses attributable to shareholders of S$7.2 million for the quarter ended 31 March 2022 (1Q2022) compared to S$5.8 million in the corresponding period (1Q2021).


Dr Ng Chin Siau, Chief Executive Officer of Q&M Dental said, "We are heartened by our continuous strong performance in 1Q2022 following a record-setting year FY2021. Our core dental business will remain strong, and with the abolishing of most of the pandemic restrictions, a positive impact on the economy, we are looking forward to resuming our growth trajectory of expanding our network of clinics in the coming quarters."

Growth & Expansion in Operations

As at 31 March 2022, the Group's number of dental outlets in Singapore has grown to 99, from 85 as at 31 March 2021. Similarly in Malaysia, the number of dental outlets has increased to 41, as compared to 36 previously.

The Group also continues to focus on its expansion into medical diagnostics, with its associated Company, Aoxin Q&M Dental Group Limited and through its recent acquisition of 49% shareholding of Acumen Diagnostics Pte. Ltd., raising Q&M's effective interest in Acumen Diagnostics from 51% to 67%. In the near term, Acumen Diagnostics' clinical testing laboratory will roll out its pipeline of new tests, including PCR assays for dengue, sepsis and, identification of bacterial pathogens and their associated antibiotics resistance in pneumonia and bloodstream infections. Its longer-term plans include the development of new vaccines.

For 1Q2022, revenue contribution from dental and medical clinics was relatively unchanged with a marginal decrease of 2% to S$38.6 million, despite the challenges of the tightening of Safe Management Measures (SMM) due to the rapid spread of the Omicron variant. Revenue contribution from medical laboratory and dental equipment & supplies segment surged by 80% to S$8.2 million on the back of increased revenue from Covid-19 testing from Acumen Diagnostics, the Group's medical laboratory business, which obtained its medical laboratory license in September 2020.

The Group's net profit after tax excluding other gains or losses for 1Q2022 increased by 25% to S$7.2 million, from S$5.8 million in the corresponding period last year, translating to an earnings per share of 0.69 Singapore cent.

As at 31 March 2022, the Group had cash and cash equivalents of S$43.5 million with net assets of S$94.9 million. This translates to Net Asset Value per share of 10.10 cents per share.

Outlook & Further Expansion Plans

With the opening up of the Singapore economy gathering pace in 2022, the country expects to see businesses ramping up in most sectors with those that were most severely affected by the pandemic like F&B, tourism to especially benefit. The government is forecasting GDP growth of between 3.0 to 5.0% in 2022, Barring any major changes in the global macroeconomic and political situation or any new adverse developments in the evolving Covid-19 situation, the Group is cautiously optimistic on its business outlook.
The Group intends to continue executing the business plans outlined below:

- Expansion of network of dental clinics in Singapore and Malaysia

The Group currently operates 99 clinics in Singapore. With the economy opening up in 2022, the Group will also intensively increase its reach through organic growth of its dental clinic network in Singapore. This will be supported by an expansion of its team of dentists to undergird the future growth of its operations in Singapore. We will continue to develop, invest and optimise our digital Artificial Intelligence (AI) guided clinical decision support system to provide the most effective and suitable treatment plans for patients. The Group believes it is well-positioned to cater to the rising demand for primary and high-value specialist dental healthcare services of its patients.

Currently, the Group operates 41 clinics in Malaysia. The clinics are located in Johor (16 dental clinics), Kuala Lumpur (9 dental clinics), Selangor (11 dental clinics), Melaka (4 dental clinics) and 1 dental clinic in Negeri Sembilan.

The Group intends to open at least 30 dental clinics a year from 2021 onwards in Singapore and Malaysia for the next 10 years. The eventual number of dental outlets will depend on available opportunities, pertinent market conditions and the evolving Covid-19 situation.

- Expansion into private dental healthcare market in the People's Republic of China ("PRC")

The main thrust of the Group's proposed expansion in PRC is through organic growth to develop a new and sustainable growth pillar that can yield long term value for the Group.

- Expansion in Southeast Asia

The Group is continuously looking out for strategic opportunities to expand its dental business and regional footprint to other Southeast Asian countries.

- Medical Laboratory

The Group will focus on rolling out its clinical testing laboratory pipeline of new tests including PCR assays for dengue sepsis and identification of bacterial pathogens and their associated antibiotics resistance in pneumonia and bloodstream infections.

Please see links for PDF documents from SGXNET.
Results: https://tinyurl.com/QnM-1Q2022-Result
Press Release: https://tinyurl.com/QnM-1Q-2022-Release

About Q&M Dental Group (Singapore) Limited (QC7.SI)

Q&M Dental Group (Singapore) Limited (QC7.SI) ("Q&M" or together with its subsidiaries, the "Group") is a leading private dental healthcare group in Asia.

The Group owns the largest network of private dental outlets in Singapore, operating 99 dental outlets across the country. Underpinned by about 290 experienced dentists and over 350 supporting staff, the Group sees an average of 40,000 patient visits a month in Singapore. The Group also operates 5 medical clinics and a dental supplies and equipment distribution company.

Outside of Singapore, the Group has 41 dental clinics and a dental supplies and equipment distribution company in Malaysia, as well as a dental clinic in the People's Republic of China ("PRC"). Q&M is also the substantial shareholder of Aoxin Q&M Dental Group Limited, a dental Group listed on the Catalist board of the Singapore Exchange that operates dental clinics and hospitals primarily in the north- eastern region of the PRC. The Group aims to expand its operations geographically and vertically through the value chain in Malaysia, the PRC and within the ASEAN region.

The Q&M College of Dentistry was established in 2019 to offer postgraduate dental education as part of its commitment to continual education and professional development of dentists. It offers Singapore's first private postgraduate diploma programme in clinical dentistry.

In 2020, the Group expanded into the medical laboratories and research industry with the strategic investment into Acumen Diagnostics Pte. Ltd. ("Acumen"). Acumen currently focuses on the manufacture, sale and distribution of COVID-19 diagnostic test kits, as well as COVID-19 testing. It is also working to roll out a pipeline of new tests, including PCR assays for dengue, sepsis and, identification of bacterial pathogens and their associated antibiotics resistance in pneumonia and bloodstream infections.

EM2AI Pte Ltd, a wholly-owned subsidiary of the Group that focuses on developing AI-powered solutions to diagnosis and treatment planning has rolled out IDMS, enabling dentists within the Group's network to administer ethical treatment plans for patients.

The Group was listed on the Mainboard of the Singapore Exchange Securities Trading Limited ("SGX- ST") on 26 November 2009. For more information on the Group, please visit www.QandMDental.com.sg

For more information, please contact:
Waterbrooks Consultants Pte Ltd
Wayne Koo
Tel: +65 9338-8166
Email: wayne.koo@waterbrooks.com.sg

Derek Yeo
Tel: +65 9791-4707
Email: derek@waterbrooks.com.sg

Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.com

source https://www.acnnewswire.com/press-release/english/75137/

昭和電工、2022年12月期第1四半期決算を発表

TOKYO, May 11, 2022 - (JCN Newswire) - 昭和電工株式会社(TSE:4004)は本日、2022年12月期第1四半期決算を発表しました。

詳細は下記URLをご参照ください。

- 2022年12月期第1四半期決算短信〔日本基準〕(連結)
https://www.sdk.co.jp/assets/files/ir/library/yoyaku_tanshin2022-1q.pdf

- 2022年12月期第1四半期決算説明資料
https://www.sdk.co.jp/assets/files/ir/library/pdf_presentation/setsumei2022-1q.pdf

概要:昭和電工株式会社

詳細は www.sdk.co.jp をご覧ください。

お問い合わせ先
昭和電工株式会社
ブランド・コミュニケーション部 広報グループ
03-5470-3235


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/Aaepd8I

Showa Denko Announces 2022 First Quarter Financial Results

TOKYO, May 11, 2022 - (ACN Newswire) - Showa Denko K.K. (SDK; TSE:4004) today announced its 2022 first quarter financial results.

- 2022 First Quarter Consolidated Financial Statements and summary
https://www.sdk.co.jp/assets/files/english/ir/library/fss2022-1q.pdf

The Company also issued the following supporting release:

- 2022 First Quarter Financial Results: Presentation Material
https://www.sdk.co.jp/assets/files/english/ir/library/pdf_presentation/results2022-1q.pdf

About Showa Denko K.K.

Showa Denko K.K. (SDK; TSE:4004, ADR:SHWDY) is a major manufacturer of chemical products serving from heavy industry to computers and electronics. The Petrochemicals Sector provides cracker products such as ethylene and propylene, the Chemicals Sector provides industrial, high-performance and high-purity gases and chemicals for semicon and other industries, the Inorganics Sector provides ceramic products, such as alumina, abrasives, refractory/graphite electrodes and fine carbon products. The Aluminum Sector provides aluminum materials and high-value-added fabricated aluminum, the Electronics Sector provides HD media, compound semiconductors such as ultra high bright LEDs, and rare earth magnetic alloys, and the Advanced Battery Materials Department (ABM) provides lithium-ion battery components. For more information, please visit www.sdk.co.jp/english/.

Media contact:
Showa Denko K.K., Public Relations Group, Brand Communication Department, Tel: 81-3-5470-3235

Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.com

source https://www.acnnewswire.com/press-release/english/75120/

三菱重工エンジニアリング、カナダに脱炭素事業の営業拠点を設立

TOKYO, May 11, 2022 - (JCN Newswire) - 三菱重工グループの三菱重工エンジニアリング株式会社(MHIENG、社長:寺沢 賢二、本社:横浜市西区)は、カナダ西部のアルバータ州カルガリーに脱炭素事業の営業拠点「Mitsubishi Heavy Industries Engineering(Calgary Branch Office)」を設立しました。当社グループの知見を結集して取り組むエナジートランジション戦略の一環として、MHIENGが有する世界トップシェアのCO2回収技術をさらにグローバルに展開するべくタイムリーな営業活動を推進し、同国におけるプレゼンス向上を図ります。

環境保全に積極的な取り組みを進めるカナダは、CO2を回収して転換利用や貯留を行うCCUS(Carbon dioxide Capture, Utilization and Storage)の有望市場です。同国では2019年に連邦炭素税が導入され、2030年までに段階的に税額を増やしていく予定であり、各州においても脱炭素関連プロジェクト向けの補助金制度が導入されています。また、輸送や貯留といったCCUSを成立させるための各種インフラも整備されつつあり、アルバータ州、サスカチュワン州をはじめとした各州で、数多くのプロジェクトについて具体的な検討が進められています。

今回の営業拠点設立により、こうしたカナダ市場の動向や顧客ニーズへの迅速な対応が可能となります。脱炭素事業における海外拠点としては、北米統括拠点のMHIA(米国三菱重工業)ヒューストンにあるエンジニアリング事業部「ESD(Engineered Systems Department)」に加え、昨年7月に設置したMHI-EMEA(欧州・中東・アフリカ三菱重工業)ロンドン本社の脱炭素事業拠点「DBD(Decarbonization Business Department)」があり、CCUS導入に先進的な地域への営業体制を強化中です。

三菱重工グループでは、エナジートランジションの事業強化に戦略的に取り組んでおり、CO2エコシステムの構築はその中の柱の一つです。CO2を回収して転換利用や貯留を行うCCUSは、カーボンニュートラル社会を実現するための有効な手段として注目されています。エナジートランジション戦略の一翼を担うMHIENGは、高性能なCO2回収技術をグローバルに展開することを通じて、脱炭素分野のリーディングカンパニーとして地球規模での温室効果ガス排出削減に貢献するとともに、地球環境保護に寄与する独自技術のさらなる開発に向けた取り組みを継続していきます。

本リリースの詳細は下記をご参照ください。
https://www.mhi.com/jp/news/22051101.html

三菱重工グループについて

三菱重工グループは、エンジニアリングとものづくりのグローバルリーダーとして、 1884年の創立以来、 社会課題に真摯に向き合い、人々の暮らしを支えてきました。長い歴史の中で培われた高い技術力に最先端の知見を取り入れ、カーボンニュートラル社会の実現 に向けたエナジートランジション、 モビリティの電化・知能化、サイバー・セキュリティ分野 の発展に取り組み、 人々の豊かな暮らしを実現します。詳しくは: 三菱重工グループのウェブサイト: www.mhi.com/jp


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/Aaepd8I

昭和電工、アンモニアおよび関連製品の販売価格改定を発表

TOKYO, May 11, 2022 - (JCN Newswire) - 昭和電工株式会社(社長:髙橋 秀仁)は、アンモニアの国内販売価格を以下のとおり引き上げることを決定いたしました。

1.価格改定の内容

(1)対象製品および値上げ幅
液化アンモニア(タンクローリー)48円/kg以上
液化アンモニア(ボンベ)48円/kg以上
アンモニア水(25%濃度)12円/kg以上

(2)実施時期
2022年5月20日納入分より

2.価格改定の背景

アンモニアは、ナイロンやアクリロニトリル等の合成繊維原料、火力発電所等の排煙に含まれる窒素酸化物(NOx)の除去、自動車・建設機械部品の金属表面処理などの一般工業用途や肥料用途などに幅広く使用されています。

アンモニアを取り巻く事業環境は、昨今の原燃料高を背景とした原材料や電力コスト等の高騰により、大変厳しい状況が続いております。当社では、製造原価の低減、経費の削減や物流の効率化等、コスト削減に努めてまいりましたが、今後も安定生産と安定供給を維持するためには、お客様にコスト上昇分の一部についてご負担をお願いせざるを得ないとの結論に至りました。

本リリースの詳細は下記URLをご参照ください。
https://www.sdk.co.jp/news/2022/42076.html

概要:昭和電工株式会社

詳細は www.sdk.co.jp をご覧ください。

お問い合わせ先
ブランド・コミュニケーション部 広報グループ
03-5470-3235


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/Aaepd8I

NexBloc Accepted into the Filecoin Faber Accelerator for Building Out Deep-Tech Web 3.0 Solutions

NEW YORK, May 11, 2022 - (ACN Newswire) - NexBloc (https://nexbloc.com) today announced the acceptance into the Filecoin Faber Accelerator (FFA). The FFA provides workshops, peer mentoring, expert advising, access to investment, and support beyond the end of the program. NexBloc will work closely with Mentors such as Protocol Labs, MetaMask, The Graph, and others to refine their business strategy and product fit for market success.


NexBloc is developing infrastructure for the decentralized web with their domain naming system (dDNS) to make Web 3.0 a usable ecosystem of connected websites and applications. They use an omnichain approach by creating root domains on core blockchains and then interconnecting any blockchain for use of a consistent naming path.

According to the Faber team, "The Filecoin Faber Accelerator was born out of a partnership between Faber (https://faber.vc) and Protocol Labs (https://protocol.ai) to help foster the development of the next generation of the internet. The partnership combines Faber's experience as early-stage deep tech VC and Protocol Labs' Web3 expertise to help entrepreneurs create the building blocks of successful new companies in the decentralized web."

Dana Farbo, Founder and CEO of NexBloc stated, "We are proud to have been selected by Faber, and the Filecoin and IPFS teams at Protocol Labs to represent the decentralized DNS space for the Accelerator. We believe that a proper domain-naming system that is interoperable with other pioneers in the space paves the way for a decentralized internet that is user friendly, secure, and scalable."

About NexBloC

NexBloc is building the next generation of the internet with decentralized DNS at the core. Digital entities tied to the decentralized web are the future of personal data protection and use.

Founded as a USA company in 2020, NexBloc uses technology stacks to create custom deployments of dDNS systems. They currently have over ten private decentralized top-level domains (dTLD) in various forms of deployment.

- Domain Website: https://domain.nexbloc.com/
- Website: https://www.nexbloc.com/
- LinkedIn: https://www.linkedin.com/company/80164369
- Medium: https://medium.com/nexbloc
- Twitter: https://twitter.com/nexbloc
- Telegram: https://t.me/nexbloc

About Faber

Faber is a Lisbon-based VC firm that invests in teams transforming the world with technology.
The firm combines a specialist focus on deep tech early-stage startups with thematic funds, dedicated investment teams, and expert advisors to actively help founders build global companies powered by frontier technologies.

Investing since 2013 with a unique approach in Southern Europe, the firm has been an early investor in hard tech companies such as Unbabel, SWORD Health, Codacy, or YData. Alongside its AI/Data- and ClimateTech-focused funds, Faber has now launched a Web3-focused investment and acceleration program in partnership with Protocol Labs. faber.vc

About Protocol Labs and Filecoin

Protocol Labs is an open-source research, development, and deployment laboratory. Our projects include IPFS, Filecoin, libp2p, and many more. We aim to make human existence orders of magnitude better through technology. We are a fully distributed company. Our team of more than 100 members works remotely and in the open to improve the internet - humanity's most important technology - as we explore new advances in computing and related fields. protocol.ai

Filecoin, the world's largest decentralized network, allows users to store, request, and transfer data via a verifiable marketplace. Filecoin is completely open-source, enabling people from all over the world to participate. The Filecoin protocol runs on an advanced and novel proof system - a combination of Proof of Spacetime (PoSt) and Proof of Replication (PoRep), to provide unmatched efficiency and reliability. Filecoin's advanced technology provides a robust foundation to store the world's most valuable data sets. An alternative to costly cloud storage, the Filecoin network offers efficiently priced and geographically decentralized storage, minimizing financial barriers and allowing users to take advantage of its unmatched network capabilities. www.filecoin.io.

Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.com

source https://www.acnnewswire.com/press-release/english/75111/